Scottsdale, AZ -- (SBWIRE) -- 01/25/2013 -- Universal pennystocks.com focus is on Hot Penny Stocks that trade on OTCBB and OTC markets, which are mostly referred to as “penny stocks”. These Penny Stocks could offer the greatest potential return on your short or long term investment. Sign up for our free newsletter before you miss the next alert.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) declared the pricing on an offered sale of up to $300 million in stock which will essentially go to the introduction of the company’s leukemia drug, Iclusig. The U.S. Food and Drug Administration approved the drug in December, which drives by the general name of ponatinib, the Cambridge, Mass. biotech’s first drug to enter the market.
In the last trading session, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) moved down -2.37% and closed at $19.38 with the overall traded volume of 11.99 million shares more than the average volume of 3.45 million. Stock price 52 weeks high was $25.40 and 52 weeks low price was $13.92. ARIA has market cap of 3.23 billion.
Has ARIA Found The Bottom and Ready To Move Up? Find Out Here
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) shares fell after the company reported European Union regulators still have questions about its weight-loss drug Belviq. Arena requested European Union regulators to approve Belviq in March 2012. The company has been operating to discourse worries raised by regulators as it attempts to gain marketing authorization. Arena anticipates the counseling committee to issue anendorsement during the first half of 2013.
In the last trading session, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) declined -0.12% to close at $8.67 and its total traded volume was 8.37 million shares. ARNA has current ratio of 9.34 and its total debt-to-equity ratio is 0.64.
Has ARNA Found The Bottom And Ready To Gain Momentum? Find Out Here
Dendreon Corporation (NASDAQ:DNDN) jumped +2.11% with the closing price of $6.30. The overall volume in the last trading session was 8.20 million shares. Its fifty two week range was $3.69-$17.04. The total market capitalization remained $972.20million.
DNDN is ahead its 52 week low with 70.73% and its last month price volatility remained 4.94%. Its beta coefficient was 3.94 with a target price of $6.20. In its share capital DNDN has 154.32million outstanding shares while 151.05million shares have been floated in market. DNDN has insider ownership of 2.76% with its institutional ownership remained 64.18%. Company’s current year earnings per share grew with 27.32% while the five year EPS growth rate was +12.65%.
What was the Moving Force behind DNDN On Bullish Run? Read This Research Report on DNDN
About Universal Penny Stocks
universalpennystocks.com is an Independent Company, our focus is on small cap stocks that trade on OTCBB and OTC markets, and are mostly referred to as “penny stocks”. These are stocks that normally trade under $5 a share and could offer the greatest potential return on your short or long term investment. You must read our Disclaimer page for more information regarding conflicts of interest and the risks involved.
We try to spot stocks in all types of market conditions. In addition, we provide emerging small cap companies with profiling and investor relations services for compensation. If you believe your company is an emerging company, with a solid product, or a company that offers our members a profitable short or long term opportunity please feel free to send us an e-mail and we’ll review the company and reply to your inquiry promptly. Please provide as much information you believe we’ll need to review your request.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)